NYSE:ABBV - AbbVie Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$79.34 +0.67 (+0.85 %)
(As of 04/26/2019 04:31 AM ET)
Previous Close$78.67
Today's Range$76.91 - $80.47
52-Week Range$75.77 - $107.25
Volume10.35 million shs
Average Volume6.62 million shs
Market Capitalization$117.03 billion
P/E Ratio10.03
Dividend Yield5.44%
Beta1.16
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$9.4228 per share
Book Value($5.61) per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees30,000
Outstanding Shares1,475,083,000
Market Cap$117.03 billion
Next Earnings DateN/A
OptionableOptionable

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 21st. Investors of record on Monday, April 15th will be given a dividend of $1.07 per share on Wednesday, May 15th. This represents a $4.28 dividend on an annualized basis and a yield of 5.39%. The ex-dividend date is Friday, April 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has initiated a stock repurchase program on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings results on Thursday, April, 25th. The company reported $2.14 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.08. The company earned $7.83 billion during the quarter, compared to analysts' expectations of $7.81 billion. AbbVie had a net margin of 17.36% and a negative return on equity of 439.07%. The company's revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.87 earnings per share. View AbbVie's Earnings History.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $8.73-8.83 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.67. AbbVie also updated its FY 2019 guidance to $8.73-8.83 EPS.

What price target have analysts set for ABBV?

17 brokers have issued twelve-month price targets for AbbVie's shares. Their forecasts range from $65.61 to $135.00. On average, they anticipate AbbVie's stock price to reach $94.0871 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

News headlines about ABBV stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 27,575,807 shares, an increase of 20.4% from the March 29th total of 22,898,566 shares. Based on an average daily trading volume, of 4,952,645 shares, the days-to-cover ratio is presently 5.6 days. Approximately 1.9% of the company's shares are short sold. View AbbVie's Current Options Chain.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional investors include Ellis Investment Partners LLC (0.19%), Ronna Sue Cohen (0.13%), Retirement Systems of Alabama (0.08%), Los Angeles Capital Management & Equity Research Inc. (0.05%), Gateway Investment Advisers LLC (0.05%) and Strs Ohio (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Calamos Advisors LLC, Los Angeles Capital Management & Equity Research Inc., Avalon Advisors LLC, Eastern Bank, Rhenman & Partners Asset Management AB, First American Bank and Pennsylvania Trust Co. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Ronna Sue Cohen, Oakbrook Investments LLC, Factory Mutual Insurance Co., Pacer Advisors Inc., Decatur Capital Management Inc., 6 Meridian and Mercer Global Advisors Inc. ADV. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $79.34.

How big of a company is AbbVie?

AbbVie has a market capitalization of $117.03 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  892 (Vote Outperform)
Underperform Votes:  586 (Vote Underperform)
Total Votes:  1,478
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel